ICON Acquires MedPass International
February 19 2020 - 4:20PM
Business Wire
Acquisition expands ICON’s global Medical
Device and Diagnostic Research Services
ICON plc, (NASDAQ: ICLR) a global provider of drug and
device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries, today
announced that it has acquired MedPass International, the leading
European medical device CRO, regulatory and reimbursement
consultancy, that specialises in medical device development and
market access.
This acquisition, concluded in late January, further enhances
ICON’s Medical Device and Diagnostic Research Services, through the
addition of new regulatory and clinical capabilities in Europe. The
integration of MedPass International’s services brings noted
expertise in complex class 3 medical devices, interventional
cardiology and structural heart devices.
Founded in 1991 and headquartered in Paris, MedPass
International is the leading European Medical Device CRO and
consultancy. The company has served more than 1,000 medical device
companies, from start-ups to multi-nationals, and has contributed
to the development of hundreds of innovative devices including a
number of breakthrough technologies.
Sarah Sorrell, President and CEO, MedPass International, said:
“As the leader in Medical Device Regulation and Clinical
Development in Europe, MedPass is delighted to be joining ICON to
become the global service provider of choice in Medtech Devices and
Diagnostics.”
“The acquisition of MedPass International deepens our existing
advisory capabilities, particularly in medical device regulation,”
commented Dr. Steve Cutler, Chief Executive Officer, ICON plc. “The
medical device CRO market is experiencing strong growth due to
technical innovation, changing regulations and increasing levels of
outsourcing. This addition broadens our medical device footprint
and staff headcount across Europe, positioning us among the global
leaders in this market.”
About MedPass International Founded in 1991 by Sarah
Sorrel, MedPass is the leading European Medical Device CRO and
Regulatory and Reimbursement Consultancy. MedPass has helped to
advance the development of breakthrough medical device technologies
by offering a broad range of strategic and operational services
tailored to meet the needs of clients around the globe. MedPass is
headquartered in Paris and delivers its services through a team of
around 100 staff (a mix of full-time and contract staff). More
details on MedPass can be found on the company website
http://medpass.org.
About ICON plc ICON plc is a global provider of drug and
device development and commercialisation services to
pharmaceutical, biotechnology, medical device and government and
public health organisations. The company specialises in the
strategic development, management and analysis of programs that
support clinical development - from compound selection to Phase
I-IV clinical studies and device development from early phase
product development through pre-market and commercialization
studies. With headquarters in Dublin, Ireland, ICON currently
operates from 97 locations in 40 countries and has approximately
14,650 employees as at December 31, 2019. Further information is
available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200219005844/en/
ICON Media Contact Gareth Arnold Weber Shandwick
Telephone: (+44) 0207 418 0398 garnold@webershandwick.com
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024